Entity

Time filter

Source Type


Zhou X.,Kunming University of Science and Technology | Chen J.,Peoples First Hospital of Yunnan Province | Tang W.,Kunming University of Science and Technology
Acta Biochimica et Biophysica Sinica | Year: 2014

Long non-coding RNAs have been reported to play an important role in cellular metabolism and development. Homeobox transcript antisense intergenic RNA (HOTAIR), a long non-coding RNA, is pervasively over-expressed in most human cancers compared with non-cancerous adjacent tissues. Although many articles have reported that HOTAIR is closely associated with metastasis, epithelial-mesenchymal transition, advanced pathological stage, drug resistance, and poor prognosis, the role of HOTAIR in gene regulation and tumor development is largely unknown, and the potential molecular mechanisms are not completely clear yet. In this review, we summarized the recent progress in the study of the major functions of HOTAIR. miR-331-3p, miR-130a, miR-7, miR-141, HER2, c-MYC, WIF-1, RBM38, PTEN, and Col-1 are involved in the HOTAIR regulation network. We tried to elucidate the molecular mechanisms of HOTAIR in the aspects of tumorigenesis, metastasis, drug resistance, and regulation. © The Author 2014. Source


Zhang Y.,Peoples First Hospital of Yunnan Province | Zhao Y.,Peoples First Hospital of Yunnan Province | Pang M.,Peoples First Hospital of Yunnan Province | Wu Y.,Peoples First Hospital of Yunnan Province | And 3 more authors.
Acta Cardiologica | Year: 2016

Objective The present study was designed to compare the outcome and safety of dual antiplatelet therapies (DAPTs) in patients with acute coronary syndrome (ACS) (intermediate metabolizers [IM] or poor metabolizers [PM]) undergoing percutaneous coronary intervention (PCI). Methods and results From September 20, 2013, to June 8, 2014, the study enrolled 329 patients with ACS scheduled for PCI. Of these, 181 (55%) patients with IM or PM were randomized in a 1:1 ratio to receive either high-dose clopidogrel or ticagrelor. The high-dose clopidogrel group received a 600-mg loading dose (LD) and finally 75 mg QD, and the ticagrelor group received 180 mg LD following 90 mg b.i.d. After 6 months of DAPT, the primary end point (composition of death, stroke, recurrent myocardial infarction [MI], and stent thrombosis) occurred in 4.4% of patients receiving ticagrelor compared with 20.0% of those receiving high-dose clopidogrel (P < 0.001). Survival probability analysis revealed a higher survival rate with ticagrelor (95% survival probability) than with clopidogrel (87% survival probability), indicating that the incidence rate of death, stroke, and recurrent MI is lower with ticagrelor than with clopidogrel (HR 2.54; 95% CI: 0.89 to 7.21; P = 0.07). Although the rates of major or minor bleeding event were high in the clopidogrel vs ticagrelor groups, they did not differ significantly. Dyspnoea and hyperuricaemia were more commonly observed in the ticagrelor group than the high-dose clopidogrel group (4.5% vs 3.8%, P = 0.03; 1.1% vs 7.7%, P < 0.001). Conclusion Ticagrelor is a more efficacious and safer treatment option in IM or PM patients with ACS compared with high-dose clopidogrel. © 2016, Acta Cardiologica. All rights reserved. Source

Discover hidden collaborations